Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|February 5, 2010
The Pharma Congress Production & Technology
The Pharma Congress Production & Technology has been Germany's leading convention in the pharma environment for 11 years, combining high-class special subject matter conferences, an adjacent exhibition and directly connected hotel accommodation. Last year, nearly 400 delegates, exhibitors and visitors attended.
Advertisement
The Pharma Congress Production & Technology has been Germany's leading convention in the pharma environment for 11 years, combining high-class special subject matter conferences, an adjacent exhibition and directly connected hotel accommodation. Last year, nearly 400 delegates, exhibitors and visitors attended.
For 2010, the Pharma Congress has been completely revised, introducing a number of innovations: this year, it will be comprised of seven conferences, two of which are the international events "Barrier Systems" and "Current Aseptic Technologies" conducted in cooperation with the European Compliance Academy (ECA). Moreover, rather than registering for a single conference, for the first time delegates will be able to buy daily tickets for 490 Euros, enabling them to attend any of the lectures of all conferences on that specific congress day.
In addition to the conferences, the Congress also provides delegates with the opportunity to get the latest information on new technologies, products and services at the parallel exhibition. This year, more than 70 internationally oriented exhibitors registered. This exhibition will also be open free of charge to visitors not attending any of conferences. To be able to only visit the exhibition, though, it will be necessary to register online in advance.
The Pharma Congress 2010 will take place in Duessseldorf/Neuss, Germany, from 9-10 March 2010. To find out more about this industry meeting point please visit
ContactCONCEPT HEIDELBERG
Rischerstrasse 8
69123 Heidelberg
Germany
Phone: +49 6221 84 44-0
E-Mail:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement